{"slug":"retatrutide-glp-1","verification":{"valid":true,"entries":2,"head":"cd52755a52f090f8ffefd8870f4cfa8e99ade3f51b706edf58c75986a9ad9dd8"},"energy":{"passes":2,"tokens_in":45382,"tokens_out":3923,"tokens_total":49305,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"cd52755a52f090f8ffefd8870f4cfa8e99ade3f51b706edf58c75986a9ad9dd8"},"provenance":[{"ts":"2026-06-30T01:00:17.688Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Glp 1\nSlug: retatrutide-glp-1\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chai","response":"{\n  \"slug\": \"retatrutide-glp-1\",\n  \"title\": \"Retatrutide and GLP-1 Agonists: Evidence on Metabolic Load Reduction\",\n  \"body\": \"## What's breaking down\\n\\nExcess body weight increases compressive forces on the spine, hips, knees, and other joints. Each pound of body weight adds roughly four pounds of load to the lower back during normal activity. Over time this mechanical stress contributes to tissue wear that outpaces natural repair. At the same time, excess adiposity drives chronic low-grade inflammation and insulin resistance that further impair metabolic repair pathways. Retatrutide and the broader GLP-1 agonist class are studied primarily for their effects on body weight and related metabolic signals rather than direct tissue regeneration at the joint or disc level.\\n\\n## Why Retatrutide might help you\\n\\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nRetatrutide activates three receptors: GLP-1, GIP, and glucagon. The glucagon component is linked to increased energy expenditure in addition to appetite effects shared with other incretin agonists. Human phase 2 data showed continued weight decline without plateau through 48 weeks. Phase 3 data later confirmed larger reductions sustained to 80–104 weeks. The resulting drop in body mass directly lowers daily joint loading. This load reduction is the primary mechanism discussed for people whose condition involves weight-related mechanical stress.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\n1. Drug: GLP-1 agonists (class)\\n2. What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\\n3. Therefore ","tokens_in":45382,"tokens_out":3923,"cost":0,"prev":"genesis","hash":"92b1778c9b6c83731add861330c49df0149068ff617ded8f2250411e5bb590b9"},{"ts":"2026-07-17T02:41:16.783Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-glp-1","response":"26 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"92b1778c9b6c83731add861330c49df0149068ff617ded8f2250411e5bb590b9","hash":"cd52755a52f090f8ffefd8870f4cfa8e99ade3f51b706edf58c75986a9ad9dd8"}]}